Xencor (XNCR) Equity Income (2021)
Xencor's (XNCR) quarterly Equity Income came in at $18.3 million in Q2 2021, up 1829900.0% on a QoQ basis from $1000.0 in Q1 2021.
Xencor (XNCR) Equity Income (2021) Analysis & Trends
Xencor (XNCR) has 1 years of Equity Income data on file, last reported at $18.3 million in Q2 2021.
- On a quarterly basis, Equity Income changed N/A year-over-year to $18.3 million in Q2 2021; TTM through Dec 2021 was $18.3 million, a N/A change from a year earlier, with the FY2021 full-year figure at $18.3 million, up 2184.77% from the prior year.
- Equity Income for Q2 2021 stood at $18.3 million, up from $1000.0 in the prior quarter.
- Over the last five years, Equity Income for XNCR reached as high as $18.3 million in Q2 2021 and fell as low as $1000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 18.30 Mn |
| Mar 31, 2021 | 1,000.00 |